Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular signalling. 2009 Aug;21(8):1255-68.   PMCID: PMC2770888
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Jul;19(5):929-33.   PMCID: PMC2722934
Stiffler JD, Nguyen M, Sohn JA, Liu C, Kaplan D, Seeger C. Focal distribution of hepatitis C virus RNA in infected livers. PLoS One. 2009 Jan;4(8):e6661.   PMCID: PMC2722721
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15;115(10):2081-91.   PMCID: PMC2875773
Abramowitz MC, Pollack A. Postprostatectomy radiation therapy for prostate cancer. Semin Radiat Oncol. 2008 Jan;18(1):15-22.
Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell cycle (Georgetown, Tex). 2008 Oct;7(19):2949-55.   PMCID: PMC2626174
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-83.
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008 Jan;6 Suppl 4:S1-S25; quiz S26-S27.
Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. American journal of clinical pathology. 2008 Oct;130(4):604-12.
Eade TN, Horwitz EM, Ruth K, Buyyounouski MK, D'Ambrosio DJ, Feigenberg SJ, Chen DY, Pollack A. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008 Jun;71(2):338-45.
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-S20; quiz S21-S22.
Heckman CJ, Coups EJ, Manne SL. Prevalence and correlates of indoor tanning among US adults. J Am Acad Dermatol. 2008 May;58(5):769-80.   PMCID: PMC2601681
Held-Warmkessel J. Caring for a patient with metastatic prostate cancer. Nursing. 2008 Jun;38(6):52-6.
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, National Comprehensive Cancer N. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008 Jul;6(6):594-622.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. J Thorac Oncol. 2008 Sep;3(9):1032-8.
Jordan VC. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer. 2008 Jan;44(1):30-8.   PMCID: PMC2566958
Konski A, Garcia M, John M, Krieg R, Pinover W, Myerson R, Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008 Sep;72(1):114-8.   PMCID: PMC2570743
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Jun 15;112(12):2635-45.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use drug therapy Male pathology Female Middle Aged Aged Adult Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols therapy adverse effects Squamous Cell Carcinoma Monoclonal Antibodies metabolism Epidermal Growth Factor Receptor Protein Kinase Inhibitors 80 and over Aged genetics Head and Neck Neoplasms administration & dosage Prognosis Clinical Trials as Topic Prostatic Neoplasms Neoplasm Staging Survival Rate secondary Neoplasm Drug Resistance antagonists & inhibitors Breast Neoplasms Piperazines Lung Neoplasms Combined Modality Therapy Androgen Antagonists Salvage Therapy antagonists & Taxoids Signal Transduction Prostatectomy radiotherapy Radiation Injuries inhibitors Risk Factors Pyrimidines diagnosis pharmacology Paclitaxel methods drug effects Neoplasm Metastasis Gastrointestinal Stromal Tumors mortality analogs & derivatives Adolescent Non-Small-Cell Lung Carcinoma Spleen Uterine Cervical Neoplasms Colostomy Maximum Tolerated Dose Skin Neoplasms Age Factors epidemiology Survival Analysis Western Blotting blood Rats surgery Hepatitis C Multivariate Analysis Drug Delivery Systems Life Expectancy Acute Disease Monte Carlo Method Local Neoplasm Recurrence Sunscreening Agents Immunohistochemistry Autopsy dosage Peripheral Nervous System Diseases Follow-Up Studies Pyrroles Palliative Care Intensity-Modulated Radiotherapy Liver etiology Patient Education as Topic Prevalence Treatment Outcome Urogenital System Prednisone Social Support Psychological Adaptation adverse Adenocarcinoma history Markov Chains statistics & numerical data 21st Century History Antineoplastic Antibiotics Practice Guidelines as Topic Lymph Nodes effects Quinazolines European Continental Ancestry Group Viral RNA Fluorouracil United States radiation effects Patient Care Team Interferons Hodgkin Disease Raloxifene Hepacivirus Gonadotropin-Releasing Hormone administration & Monoclonal Antibodies-Murine-Derived Cell Cycle Carboplatin economics chemically induced Hematologic Diseases Oncologic Nursing chemistry 20th Century History Doxorubicin Vincristine Epothilones Forecasting Mitomycin Disease-Free Survival B-Lymphocytes Prostate-Specific Antigen Interdisciplinary Communication Recurrence Deoxycytidine Adjuvant Radiotherapy Child Cyclophosphamide prevention & control Gene Dosage Indoles Drug Administration Schedule Brachytherapy Iodine Radioisotopes Osteoporosis Economic Models Somatomedins Sirolimus Proto-Oncogene Proteins c-ret Hormonal Antineoplastic Agents
Last updated on Wednesday, February 05, 2020